David Sancho, Group Leader at CNIC shared on LinkedIn:
“Are you interested in cancer immunotherapy?
Do you have experience with mouse or human DCs?
Do you want to join us in a challenging project in Madrid to find new DC checkpoints?
Apply for the position with us! only one week left!!!
See enclosed pdf for your application!
Deadline: 31st October”
More about the objectives of CNIC-led project
The TARGET-DC project aims to discover novel dendritic cell regulatory molecules that could strengthen antitumor immunity.
By combining genomic analysis, animal models, and human samples, researchers will investigate dendritic cell – T-cell interactions and develop antibodies to modulate these pathways. The project seeks to advance promising discoveries from basic research to preclinical validation, potentially improving immunotherapy responses and addressing
- treatment resistance
- tumor progression
- relapse.
It also aims to support personalized cancer treatment and facilitate clinical translation through patent development and collaboration with pharmaceutical industry partners.
You may also be interested in:
Pembrolizumab: What Determines Response to PD-1 Blockade?
